BioInvent signs antibody discovery deal with HGS
This article was originally published in Scrip
Executive Summary
BioInvent and Human Genome Sciences (HGS) have signed a deal to discover, develop and commercialise therapeutic monolconal antibodies that target antigens discovered by HGS.